How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of age, disability, gender reassignment, pregnancy and maternity, race, religion or belief, sex or sexual orientation?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Draft guidance consultation

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about loncastuximab tesirine

Marketing authorisation indication

2.1 Loncastuximab tesirine (Zynlonta, Swedish Orphan Biovitrum) is indicated for 'the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy.'

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics for loncastuximab tesirine.

Price

2.3 The list price for loncastuximab tesirine is £15,200 per 10 mg vial (excluding VAT; company submission). An average course of loncastuximab tesirine per person is £85,562.

2.4 The company has a commercial arrangement, which would have applied if loncastuximab tesirine had been recommended.